AR060334A1 - Derivados de benzimidazol - Google Patents
Derivados de benzimidazolInfo
- Publication number
- AR060334A1 AR060334A1 ARP070101297A ARP070101297A AR060334A1 AR 060334 A1 AR060334 A1 AR 060334A1 AR P070101297 A ARP070101297 A AR P070101297A AR P070101297 A ARP070101297 A AR P070101297A AR 060334 A1 AR060334 A1 AR 060334A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- mono
- optionally substituted
- halogen
- Prior art date
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 23
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- -1 amino, carboxy Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000002825 nitriles Chemical class 0.000 abstract 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 238000005804 alkylation reaction Methods 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticmente aceptable o éster de profármaco del mismo: en donde R es halogeno o alquilo de 1 a 6 átomos de carbono opcionalmente sustituido; X se selecciona del grupo que consiste de O, NH, CH2, CO, SO, SO2, o S; Y representa un grupo seleccionado de lo siguiente: alquilo de 1 a 6 átomos de carbono opcionalmente sustituido: -SR1, -S(O)R1, -S(O)2R1, -OR2, en donde R1 y R2 se seleccionan de alquilo de 1 a 6 átomos de carbono, alquenilo de 1 a 4 átomos de carbono o alquinilo de 1 a 4 átomos de carbono, opcionalmente sustituido; el sustituyente o sustituyentes opcionales en R, R1, R2 e Y se seleccionan independientemente del grupo que consiste de halogeno, hidroxi, alquilo de 1 a 6 átomos de carbono, mono- o di- alquilamino de 1 a 6 átomos de carbono, aminocarbonilo, sulfinilo, sulfonilo, sulfanilo, mono- o di-alquilaminocarbonilo de 1 a 6 átomos de carbono, amino, carboxi, alcoxi de 1 a 6 átomos de carbono, alqueniloxi de 2 a 6 átomos de carbono, alquiniloxi de 2 a 6 átomos de carbono, cicloalquilo de 3 a 12 átomos de carbono, heterocicloalquilo de 3 a 18 átomos de carbono, alquilcarbonilo de 1 a 6 átomos de carbono, alcoxicarbonilo de 1 a 6 átomos de carbono, nitrilo, arilo; todos estos excepto el halogeno, están independiente y opcionalmente sustituidos por uno o más sustituyentes seleccionados deI grupo que consiste de halogeno, hidroxi, alquilo de 1 a 6 átomos de carbono, mono- o di- alquilamiento de 1 a 6 átomos de carbono, aminocarbonilo, sulfinilo, sulfonilo, sulfanilo, mono- o dialquilaminocarbonilo de 1 a 6 átomos de carbono, amino, carboxi, alcoxi de 1 a 6 átomos de carbono, cicloalquilo de 3 a 12 átomos de carbono, heterocicloalquilo de 3 a 18 átomos de carbono, alquilcarbonilo de 1 a 6 átomos de carbono, alcoxicarbonilo de 1 a 6 átomos de carbono, nitrilo, arilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0606426.5A GB0606426D0 (en) | 2006-03-30 | 2006-03-30 | Benzimidazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060334A1 true AR060334A1 (es) | 2008-06-11 |
Family
ID=36424926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101297A AR060334A1 (es) | 2006-03-30 | 2007-03-28 | Derivados de benzimidazol |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20100227889A1 (es) |
| EP (1) | EP2004629A2 (es) |
| JP (1) | JP2009531363A (es) |
| KR (1) | KR20080110769A (es) |
| CN (1) | CN101400669A (es) |
| AR (1) | AR060334A1 (es) |
| AU (1) | AU2007234021B2 (es) |
| BR (1) | BRPI0710180A2 (es) |
| CA (1) | CA2644380A1 (es) |
| CL (1) | CL2007000850A1 (es) |
| CR (1) | CR10199A (es) |
| EC (1) | ECSP088781A (es) |
| GB (1) | GB0606426D0 (es) |
| GT (1) | GT200800200A (es) |
| IL (1) | IL193475A0 (es) |
| MA (1) | MA30341B1 (es) |
| MX (1) | MX2008012403A (es) |
| NO (1) | NO20084543L (es) |
| PE (1) | PE20071149A1 (es) |
| RU (1) | RU2008142831A (es) |
| TN (1) | TNSN08369A1 (es) |
| TW (1) | TW200806647A (es) |
| WO (1) | WO2007112913A2 (es) |
| ZA (1) | ZA200806833B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
| ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
| KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
| JP2014500882A (ja) * | 2010-11-26 | 2014-01-16 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ治療法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | ２、５、６−置換ベンズイミダゾール化合物誘導体 |
| US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| US7622592B2 (en) * | 2002-11-01 | 2009-11-24 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| GB0400781D0 (en) * | 2004-01-14 | 2004-02-18 | Novartis Ag | Organic compounds |
| EP1964548A1 (en) * | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
-
2006
- 2006-03-30 GB GBGB0606426.5A patent/GB0606426D0/en not_active Ceased
-
2007
- 2007-03-28 EP EP07723708A patent/EP2004629A2/en not_active Withdrawn
- 2007-03-28 RU RU2008142831/04A patent/RU2008142831A/ru not_active Application Discontinuation
- 2007-03-28 WO PCT/EP2007/002763 patent/WO2007112913A2/en not_active Ceased
- 2007-03-28 US US12/295,381 patent/US20100227889A1/en not_active Abandoned
- 2007-03-28 MX MX2008012403A patent/MX2008012403A/es not_active Application Discontinuation
- 2007-03-28 AU AU2007234021A patent/AU2007234021B2/en not_active Ceased
- 2007-03-28 CA CA002644380A patent/CA2644380A1/en not_active Abandoned
- 2007-03-28 BR BRPI0710180-5A patent/BRPI0710180A2/pt not_active IP Right Cessation
- 2007-03-28 CN CNA2007800087520A patent/CN101400669A/zh active Pending
- 2007-03-28 PE PE2007000352A patent/PE20071149A1/es not_active Application Discontinuation
- 2007-03-28 JP JP2009501943A patent/JP2009531363A/ja not_active Withdrawn
- 2007-03-28 AR ARP070101297A patent/AR060334A1/es not_active Application Discontinuation
- 2007-03-28 KR KR1020087023787A patent/KR20080110769A/ko not_active Withdrawn
- 2007-03-29 TW TW096111055A patent/TW200806647A/zh unknown
- 2007-03-29 CL CL200700850A patent/CL2007000850A1/es unknown
-
2008
- 2008-08-07 ZA ZA200806833A patent/ZA200806833B/xx unknown
- 2008-08-11 CR CR10199A patent/CR10199A/es not_active Application Discontinuation
- 2008-08-14 IL IL193475A patent/IL193475A0/en unknown
- 2008-09-22 TN TNP2008000369A patent/TNSN08369A1/en unknown
- 2008-09-29 GT GT200800200A patent/GT200800200A/es unknown
- 2008-09-30 EC EC2008008781A patent/ECSP088781A/es unknown
- 2008-10-17 MA MA31302A patent/MA30341B1/fr unknown
- 2008-10-28 NO NO20084543A patent/NO20084543L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007112913A2 (en) | 2007-10-11 |
| CL2007000850A1 (es) | 2008-03-14 |
| US20100227889A1 (en) | 2010-09-09 |
| BRPI0710180A2 (pt) | 2011-08-09 |
| GB0606426D0 (en) | 2006-05-10 |
| IL193475A0 (en) | 2009-05-04 |
| JP2009531363A (ja) | 2009-09-03 |
| CA2644380A1 (en) | 2007-10-11 |
| RU2008142831A (ru) | 2010-05-10 |
| TNSN08369A1 (en) | 2009-12-29 |
| GT200800200A (es) | 2008-11-10 |
| PE20071149A1 (es) | 2007-12-04 |
| ZA200806833B (en) | 2009-05-27 |
| AU2007234021B2 (en) | 2011-04-28 |
| MA30341B1 (fr) | 2009-04-01 |
| WO2007112913A3 (en) | 2007-12-21 |
| NO20084543L (no) | 2008-10-21 |
| KR20080110769A (ko) | 2008-12-19 |
| MX2008012403A (es) | 2008-10-07 |
| CR10199A (es) | 2008-10-16 |
| EP2004629A2 (en) | 2008-12-24 |
| ECSP088781A (es) | 2008-10-31 |
| CN101400669A (zh) | 2009-04-01 |
| AU2007234021A1 (en) | 2007-10-11 |
| TW200806647A (en) | 2008-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060334A1 (es) | Derivados de benzimidazol | |
| ES2491140T3 (es) | Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación | |
| BR112014026457A2 (pt) | compostos de tetrazolinona e seu uso como pesticidas | |
| EA201200826A1 (ru) | Инсектицидные соединения, основанные на производных изоксазолина | |
| EA201101492A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
| AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| EA200802403A1 (ru) | Азолилметилоксираны, их применение для борьбы с фитопатогенными грибами, а также содержащие их средства | |
| CY1114932T1 (el) | Αντιπαρασιτικοι παραγοντες | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| CO5611131A2 (es) | Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa | |
| AR066348A1 (es) | Inhibidores de las iap | |
| NZ734896A (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| HRP20120323T1 (en) | Diarylhydantoin compounds | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| CY1112914T1 (el) | Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης | |
| MEP8409A (en) | Fused heterocyclic compound | |
| AR069702A1 (es) | Derivados de 1,2 oxazol como insecticidas | |
| AR069310A1 (es) | Inhibidores de beta- lactamasa | |
| EA201170384A1 (ru) | Пиррольные соединения | |
| EA201070138A1 (ru) | Производные плевромутилина и их применение в качестве антимикробных средств | |
| EA201170456A1 (ru) | Синергические комбинации макроциклического ингибитора вируса гепатита с и нуклеозида | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| EA201100009A1 (ru) | Соединения 1,2-бензизотиазола, полезные для борьбы с животными-вредителями | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR067691A1 (es) | Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |